US4968675A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Non-hemolytic lazaroid parenteral formulation
Assignee: Pharmacia and Upjohn Co
•
Filing: 1988-10-28
•
Granted: 1990-11-06
•
Expires: 2008-10-28
Abstract
Abstract 16 alpha -Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]pr egna-1,4,9(11)-triene-3,20-dione monomethanesulfonate causes hemolysis when injected. However, when formulated with a citric acid/sodium citrate both the hemolysis and hypotension side effects are prevented.
Inventors
- 👤 Ching-Chiang Su
- 👤 Teresa Harshman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 08:28
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K31/00; A61K31/56; A61K31/57; A61K47/00; A61K47/06; A61K47/08; A61K47/12
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
36 words
A parenteral pharmaceutical composition comprising: 16α-Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]pregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate, dimethanesulfonate or hydrochloride: 0.5-5.0 mg/ml Citric Acid Hydrate: 2-40 mM Sodium Citrate Dihydrate: 0.05-6.4 mM Sodium Chloride: 3-5 mg/ml pH: 3.0 Osmolality: 180-185 mOsm/kg Water for injection USP, qsad.
Claim 2
Dependent Claim
36 words
A parenteral pharmaceutical composition comprising: 16α-Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]pregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate, dimethanesulfonate or hydrochloride: 0.5-5.0 mg/ml Citric Acid Hydrate: 2-40 mM Sodium Citrate Dihydrate: 0.05-6.4 mM Sodium Chloride: 3-5 mg/ml pH: 3.0 Osmolality: 180-185 mOsm/kg Water for injection USP, qsad.
Claim 3
Dependent Claim
28 words
A parenteral pharmaceutical composition comprising: 16α-Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]pregna-1,4,9(11)-triene3,20-dione monomethanesulfonate: 1.5 mg/ml Citric Acid Hydrate: 20 mM Sodium Citrate Dihydrate: 3.2 mM Sodium Chloride: 4.5 mg/ml pH: 3.0 Osmolality: 183 mOsm/kg
Claim 4
Dependent Claim
28 words
A parenteral pharmaceutical composition comprising: 16α-Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]pregna-1,4,9(11)-triene3,20-dione monomethanesulfonate: 1.5 mg/ml Citric Acid Hydrate: 20 mM Sodium Citrate Dihydrate: 3.2 mM Sodium Chloride: 4.5 mg/ml pH: 3.0 Osmolality: 183 mOsm/kg
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-11-05 | 1994-05-07 | 1994-11-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-11-05 | 1998-05-07 | 1998-11-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-11-05 | 2002-05-07 | 2002-11-06 | $7700.00 | Window Closed / Lapsed |